RecruitingPHASE1, PHASE2NCT06189963

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NKGen Biotech, Inc.
Intervention
SNK01(biological)
Enrollment
36 target
Eligibility
40-85 years · All sexes
Timeline
20232026

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06189963 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials